What Quest PharmaTech does

Quest PharmaTech Inc. is a Canadian clinical-stage pharmaceutical company publicly traded on the TSX Venture Exchange (QPT:TSXV) and headquartered in Edmonton, Alberta. The company is developing Mab AR 9.6, a humanized monoclonal antibody that targets truncated O-glycan on MUC16 (the CA125 tumor marker) and blocks oncogenic signaling through the EGF receptor and alpha-4-beta integrin pathways. The platform underpins multiple product candidates spanning therapeutic antibodies for pancreatic and ovarian cancer, a near-infrared fluorescence conjugate for intraoperative imaging, an immunoPET diagnostic agent, and a radioimmunotherapy program.

The company operates a hybrid asset-development and investment-holding model. Quest owns approximately 26.6% of Korean private biotech OQPBIOM (valued at $19.8 million), a 10.67% direct interest plus 12% indirect interest in OncoVent, and exposure to OncoQuest, with OncoQuest's immunotherapy assets having been transferred to OQPBIOM. Total assets stood at $27.8 million for the fiscal year ended January 31, 2026, with 1-10 employees and no commercialized products or disclosed revenue. Leadership includes CEO Dr. Madi Madiyalakan (since August 2006) and Chairman J. Mark Lievonen (former President of Sanofi Pasteur Limited, 1999-2016).

Quest has no recurring revenue and functions as a publicly listed vehicle for clinical-stage antibody development and strategic biotech investments. Its near-term economics are driven primarily by the value trajectory of OQPBIOM rather than by internal product commercialization. Recent clinical setbacks include a Phase III Oregovomab futility failure, and the company has publicly opposed OQPBIOM's proposed acquisition of South Korea-based AdBioTech, reflecting active shareholder-level governance intervention in the investee portfolio.

Name

Quest PharmaTech

Legal name

Quest PharmaTech Inc.

Website

https://questpharmatech.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Quest PharmaTech Inc. is a TSX-V listed Canadian clinical-stage pharmaceutical company developing the Mab AR 9.6 humanized monoclonal antibody targeting MUC16 for pancreatic and ovarian cancer therapy, imaging, and radioimmunotherapy applications, operating alongside equity stakes in Korean biotech OQPBIOM and OncoVent.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Monoclonal antibody therapy
• Cancer immunotherapy
• Targeted oncology therapeutics
• Radioimmunotherapy agents
• Theranostic imaging

Headquarters

HQ city

Edmonton

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Marketing channels2 records

Core offering

Quest PharmaTech is a Canadian pharmaceutical company developing antibody-based immunotherapeutic products for cancer centered on its lead candidate Mab AR 9.6, a humanized monoclonal antibody targeting truncated O-glycan on MUC16. The product pipeline includes targeted therapy for pancreatic and ovarian cancers, a near-infrared fluorescence antibody conjugate for fluorescence-guided surgery, a radio-labeled immunoPET imaging agent, and a radioimmunotherapy approach for MUC16-expressing tumors.

Product overview

Quest PharmaTech is a Canadian pharmaceutical company developing a portfolio of cancer therapeutics and diagnostics centered around its lead product candidate Mab AR 9.6, a humanized monoclonal antibody targeting truncated MUC16. The company's product pipeline includes therapeutic applications for pancreatic cancer, fluorescence-guided surgical imaging agents, immunoPET imaging agents, and radioimmunotherapy. The company also maintains strategic investments in biotechnology companies including OQPBIOM (26.6% ownership, Korean immunotherapy developer) and OncoVent (10.67% direct + 12% indirect ownership).

Differentiator

Problem solved

Functional benefit

Products and services

• Mab AR 9.6 A humanized monoclonal antibody targeting truncated O-glycan on MUC16 for targeted cancer therapy applications, including pancreatic cancer and ovarian cancer treatment. The antibody blocks oncogenic activities and tumor growth by interfering with EGF receptor and alpha-4-beta-integrin signaling pathways. Intended for biopharmaceutical licensing partners and ultimately for oncology patients with MUC16-expressing tumors.
• Fluorescence Antibody Conjugate for Intraoperative Imaging A near-infrared fluorescent antibody conjugate derived from Mab AR 9.6 for fluorescence-guided intraoperative imaging of pancreatic cancer. Enables surgeons to visualize MUC16-expressing tumor tissue during surgery, targeting improved surgical outcomes for oncology patients.
• ImmunoPET Imaging Agent A radio-labeled immunoPET imaging agent based on Mab AR 9.6 for non-invasive imaging of ovarian and pancreatic cancer. Provides diagnostic imaging capability using a MUC16-targeted tracer for oncology clinicians and imaging centers.
• Radioimmunotherapy (Mab AR 9.6-based) A radioimmunotherapy product candidate using Mab AR 9.6 for the treatment of cancers expressing MUC16, intended as a therapeutic option for patients with MUC16-positive tumors. Developed for oncology biopharmaceutical licensing partners and ultimately oncology patients.

Quantifiable outcome

• Structural characterization of Mab AR 9.6 in complex with MUC16 revealed non-linear epitope influenced by glycosylation
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• AdBioTechminorOthers · 10 June 2025AdBioTech is a South Korea-based company proposed to be acquired by OQPBIOM. Quest PharmaTech, as the largest shareholder of OQPBIOM, has publicly opposed this acquisition citing it is not in the best interest of OQM or its shareholders and is evaluating legal options.
• OQPBIOM Inc.coreStrategic or Co-development PartnerQuest PharmaTech holds 26.6% equity interest in OQPBIOM Inc., a Korean private biotechnology company developing immunotherapy assets. OncoQuest transferred its immunotherapy assets to OQPBIOM through a series of transactions. Quest is the largest shareholder and has expressed opposition to OQPBIOM's proposed acquisition of AdBioTech.
• OncoVentcoreStrategic or Co-development PartnerQuest holds 10.67% direct ownership interest in OncoVent plus 12% indirect interest through its ownership in OncoQuest. OncoQuest owns 29% of OncoVent. OncoVent is linked as a partner company on Quest's website.
• OncoQuestcoreStrategic or Co-development PartnerOncoQuest transferred immunotherapy assets to OQPBIOM. Quest maintains an ownership position in OncoQuest as part of its investment structure. OncoQuest Pharma USA Inc. is a Delaware-incorporated subsidiary.
• CanariabiominorOthersCanariabio is listed as a linked partner company on Quest PharmaTech's website. Nature of relationship is not explicitly detailed.
• OncoQuest Pharma USA Inc.coreOthersDelaware-incorporated company and subsidiary of OncoQuest. Filed Form D notice for $360,000 USD exempt securities offering in the United States.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• ImmunoGen (AbbVie): Antibody-drug conjugate developer focused on oncology, including ovarian cancer. Directly comparable to Quest in developing antibody-based targeted cancer therapeutics leveraging tumor antigens.
• Medicenna Therapeutics: Canadian clinical-stage immunotherapy company developing antibody-based oncology therapeutics. Closely comparable as a small Canadian biotech pursuing novel cancer biologics with similar scale and stage.
• MacroGenics: Clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. Directly comparable in focusing on engineered monoclonal antibodies and antibody-drug conjugates for oncology indications.
• BriaCell Therapeutics: Canadian clinical-stage biotech developing immunotherapy for cancer (notably breast cancer). Comparable as a small Canadian oncology immunotherapy developer with similar development-stage positioning.

Broad incumbents

• Daiichi Sankyo: Global pharmaceutical leader in antibody-drug conjugates (DXd platform). Comparable as a developer of antibody-conjugate oncology therapeutics, though operating at vastly greater scale and breadth.
• AstraZeneca: Global pharmaceutical company with significant ovarian cancer franchise (including anti-MUC16 initiatives). Comparable as a developer of MUC16-targeted and ovarian cancer therapies, though at vastly greater scale.
• Seagen (Pfizer): Established oncology antibody-conjugate company (now part of Pfizer). Comparable as a developer of antibody-based targeted cancer therapeutics and antibody-drug conjugates, though at much greater scale.

Regional players

• Helix BioPharma: Canadian clinical-stage biopharmaceutical company developing immunotherapies for cancer. Comparable as a small Canadian oncology biotech with similar jurisdictional and capital-market profile.
• Oncolytics Biotech: Canadian clinical-stage biotech developing immuno-oncology therapeutics (pelareorep). Comparable as a small Canadian oncology immunotherapy developer with similar jurisdictional profile.

Emerging players

• CytomX Therapeutics: Clinical-stage oncology developer using Probody platform to engineer antibody-based therapeutics with tumor-selective activity. Comparable in developing engineered monoclonal antibody approaches for cancer therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/quest-pharma-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quest PharmaTech